Alzheimer's disease (AD) is the most common neurodegenerative disease and the leading cause of dementia in the elderly. Accumulating evidence supports soluble amyloid-b (Ab) oligomers as the leading candidate for the causative agent in AD and synapses as the primary site of Ab oligomer action. However, the molecular and cellular mechanisms by which Ab oligomers cause synaptic dysfunction and cognitive impairments remain poorly understood. Using primary cultures of rat hippocampal neurons as a model system, we show that the partitioning defective-1 (PAR-1)/microtubule affinity-regulating kinase (MARK) family kinases act as critical mediators of Ab toxicity on synapses and dendritic spines. Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after Ab treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or Ab treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Ab, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Ab oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels. Our results reveal a critical role for PAR-1/MARK kinases in AD pathogenesis and suggest PAR-1/MARK inhibitors as potential therapeutics for AD and possibly other tauopathies where aberrant tau hyperphosphorylation is involved.
INTRODUCTION
Despite the identification of amyloid plaques (AP) and neurofibrillary tangles (NFT) as pathological hallmarks of Alzheimer's disease (AD), the memory deficits in AD patients do not correlate well with AP or NFT burden; instead, loss of synaptic markers is a better predictor of clinical symptoms and disease progression, lending support to the notion that AD is a disease of synaptic failure (1) . Synapses and dendritic spines are dynamic structures whose plasticity is thought to underlie learning and memory and contribute to AD pathogenesis (2) . Accumulating evidence supports that amyloid-b (Ab) is the primary agent causative of synaptic and spine pathology in AD (3 -5) . For example, rare genetic mutations cause familial AD by altering the production or metabolism of Ab (6, 7) , the soluble pool of which correlates with disease progression and severity (5) , and depletion of soluble Ab in mouse AD models rescues the cognitive deficits (8) . Moreover, synthetic Ab oligomers or those purified from cultured cells or brain samples can induce neuritic degeneration, neurotransmission defects and spine loss (9 -12) . The detailed cellular and biochemical mechanisms involved, however, remain poorly defined.
Recent studies have supported tau as a major mediator of Ab toxicity. In mouse models, intracranial injection of Ab or crossing an APP transgene into tau transgenic animals promoted NFT pathology (13) (14) (15) , and antibody-based removal of Ab reduced hyperphosphorylated tau and rescued * To whom correspondence should be addressed at: Department of Pathology, Stanford University School of Medicine, R270 Edwards Building, Stanford, CA 94305, USA. Tel: +1 6507231828; Fax: +1 6504986616; Email: bingwei@stanford.edu behavioral and pathological defects in an APP/Psn/tau 3xTg AD mouse model (16) . Moreover, removal of tau relieved Ab-induced neurotoxicity in culture (17) and prevented Ab-induced behavioral deficits in an h-APP Tg mouse model (18) . Together, these studies support the critical involvement of tau in mediating the toxicity of Ab in AD pathogenesis.
It is not clear how tau abnormality arises in AD. Current efforts have focused on the role of tau hyperphosphorylation (19, 20) . A number of kinases and phosphatases are shown to regulate tau phosphorylation (21) , but few of them have been examined for roles in linking amyloid with tau pathology. A strong case has been made for partitioning defective-1 (PAR-1)/microtubule affinity-regulating kinase (MARK). PAR-1 was originally identified for its role in regulating cell polarity (22) . PAR-1 and its mammalian homolog MARK phosphorylate tau associate with NFT (23, 24) . In Drosophila models, PAR-1-mediated phosphorylation is required for conferring tau toxicity (25) . Elevation of PAR-1/MARK-mediated tau phosphorylation (at the 12E8 sites) was observed in AD patients and mouse AD models (26, 27) . Activated Drosophila PAR-1 also directly phosphorylates the postsynaptic density protein 95 (PSD-95) homolog discs large (Dlg), impairing its postsynaptic localization (28) , which might be mechanistically related to the synaptic loss of PSD-95 seen in early stages of AD in patients and mouse models (29, 30) .
The studies described above strongly implicate PAR-1/ MARK kinases as critical players in AD. Consistent with this hypothesis, a recent genome-wide association study suggested a potential link of MARK4 to late onset AD (31, 32) , an observation requiring further validation, and PAR-1/ MARK kinases are activated by APP or Ab oligomers in Drosophila or mammalian neurons, respectively (33, 34) . To more rigorously test the pathogenic role of PAR-1/MARK kinases and to validate them as potential drug target, loss-of-function analysis in mammalian systems is critically needed. However, functional redundancy among at least four members of the mammalian PAR-1/MARK kinase family presents a considerable challenge for a genetic loss-of-function approach. In this study, we describe a pharmacological approach using a specific peptide inhibitor to probe the importance of PAR-1/MARK in mediating the synaptic and dendritic toxicity of Ab in primary cultures of rat hippocampal neurons. Our results provide compelling evidence that PAR-1/MARK kinases are critically involved in mediating the synaptic toxicity of Ab by promoting the aberrant phosphorylation of tau and PSD-95, and that inhibition of PAR-1/MARK kinases represents a viable therapeutic approach.
RESULTS

Overexpression of MARK4 induces defects in synapses and dendritic spines
We used cultured rat primary hippocampal neurons to test whether the PAR-1/MARK family kinases mediate AD-related neurotoxicity in mammals. In addition to being the relevant cell type for studying AD pathogenesis, these neurons offer excellent cellular resolution for studying synaptic and dendritic spine morphologies and for electrophysiological characterization. As expected, we found that overexpression of Drosophila PAR-1 or mammalian MARK4 (31) in hippocampal neurons resulted in hyperphosphorylation of tau at the phosphorylation sites recognized by the 12E8 antibody (Supplementary Material, Fig. S1 ), sites known to be phosphorylated by PAR-1/MARK (23, 25) . This was accompanied by a number of phenotypes including loss of dendritic spines (Fig. 1A -C and F) , the delocalization of PSD-95 from synapses ( Fig. 1A and F ) and decreased expression of other synaptic markers such as GluR1, a subunit of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Fig. 1B and F) , and the presynaptic protein Synapsin I ( Fig. 1C and F) . In addition, we also observed defects in mitochondria localization in PAR-1 or MARK4 overexpressing neurons (data not shown). The kinase-dead form of MARK4 (MARK4-KD) had no such effect, indicating that kinase activity is required for inducing the observed toxic effects. Both MARK4-WT and MARK4-KD exhibited relatively uniform distribution in the dendrites (Fig. 1A-C, green signals) .
Previous studies in Drosophila showed that PAR-1 could regulate the postsynaptic localization of Dlg through direct phosphorylation (28) . The phosphorylation site is conserved in PSD-95, the mammalian homolog of Dlg. To test whether MARK4 may directly act on PSD-95 to regulate its synaptic localization, we generated a mutant form of PSD-95 in which the conserved PAR-1/MARK target site is mutated to Ala (PSD-95-SA). Both the WT and SA mutant forms of PSD-95 were fused with GFP to facilitate visualization. In the same expression vector, shRNAs targeting endogenous PSD-95 but not the exogenous PSD-95-GFP were also expressed (35) . Thus, the observed effects were largely free of potential interference from endogenous PSD-95. Although PSD-95-WT-EGFP was delocalized from the dendritic spines by MARK4 and was present uniformly in the dendritic shaft, PSD-95-SA-EGFP effectively resisted the effect of MARK4 and maintained its punctate synaptic localization ( Fig. 1D and G), consistent with MARK4 directly regulating PSD-95 localization in mammalian hippocampal neurons through phosphorylation.
Expression of a non-phosphorylatable form of tau blocks PAR-1/MARK toxicity
We were interested in identifying the key substrates through which PAR-1/MARK overexpression leads to synaptic and dendritic spine toxicity. Previous studies showed that PAR-1 overexpression in Drosophila photoreceptors caused neurotoxicity through phosphorylation of tau in the microtubulebinding domain, and that a mutant form of tau with the PAR-1 site mutated (tauS2A) not only was itself non-toxic but also could block PAR-1 overexpression-induced neurotoxicity (25) . Co-transfection of a similar phosphorylation-mutant form of tau (h-tau-SA) blocked the toxic effects of MARK4 in rat hippocampal neurons, including the spine loss, whereas wild-type human tau (h-tau-WT) failed to do so ( Fig. 1E and G). This is consistent with tau being a major mediator of MARK4 toxicity on synapses and dendritic spines.
Expression of non-phosphorylatable form of tau blocks Ab toxicity
We further tested whether phosphorylation of tau by MARK might mediate the toxicity of Ab on neuronal synapses and dendritic spines. Although MARK activation and elevation of tau phosphorylation at PAR-1/MARK target sites occurred in hippocampal neurons after Ab oligomer treatment (11, 34) , it is not clear whether these events were disease-causing or simply a compensatory, protective response. Indeed, overexpression of MARK2 was reported to be able to rescue tau-induced synapse and spine loss (36) . Consistent with previous reports (11, 34) , treatment of rat hippocampal neurons with synthetic Ab, prepared using a well-characterized procedure that enriches for Ab oligomers (37) , resulted in increased tau phosphorylation at the 12E8 sites ( Fig. 2A) , suggesting that Ab treatment had activated MARK kinases. Increased phosphorylation of tau at a site recognized by the PHF-1 phospho-tau antibody was also observed (data not shown). Ab treatment also caused losses of synaptic marker expression and dendritic spines as seen in the PAR-1/MARK overexpression condition (Fig. 2B -E and G) . Strikingly, in neurons transfected with h-tau-S2A but not h-tau-WT, the toxic effect of Ab in causing spine loss was ameliorated ( Fig. 2F and G) . The toxic effects of Ab on the density of synaptic marker PSD-95 and GluR1 clusters were also rescued by h-tau-S2A (Fig. 2H) . These results support the notion that phosphorylation of tau by PAR-1/MARK family kinases is a primary downstream event by which Ab exerts its toxicity on hippocampal synapses and dendritic spines.
A PAR-1/MARK inhibitor effectively blocked Ab toxicity
Next we wished to assess the involvement of endogenous MARK kinases in mediating Ab toxicity. To circumvent potential functional redundancy among at least four mammalian MARK family members, we used a peptide inhibitor (MKI) derived from the CagA protein of Helicobacter pylori, which can specifically bind with high affinity to the substrate-binding sites of all MARKs by mimicking the natural substrates of these kinases (38) . We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous tau (Fig. 3A) and 
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transfected human tau at the 12E8 sites (Fig. 3B) . Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A) . It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation, as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites (25) . Supporting the specificity of the MKI effect on PAR-1/MARK, under similar experimental conditions MKI-EGFP did not affect the phosphorylation of acetyl-CoA carboxylase (ACC) by AMP-activated kinase (AMPK) (Fig. 3C) , which is closely related to PAR-1/MARK on the protein kinase phylogenetic tree (39) . MARK4 overexpression-induced synaptic defects including spine loss ( Fig. 3D and E) and reduction of PSD-95 and GluR1 puncta density were all effectively blocked by MKI-EGFP (Fig. 3E) .
To test the function of MARK kinases in mediating the toxicity of Ab on synapses and dendritic spines, we next examine the effect of MKI in modulating the toxicity of Ab. Remarkably, MKI-GFP expression effectively blocked the morphological defects caused by Ab, such as the loss of dendritic spines (Fig. 4A-C) , and the reduction in the density of PSD-95 ( Fig. 4A and C) and GluR1 puncta ( Fig. 4B and C) .
We further examined the effect of MKI-EGFP at the functional level by performing electrophysiological analysis. Ab treatment caused a reduction in the frequency but not in the amplitude of AMPAR-mediated miniature excitatory postsynaptic current (mEPSC) (Fig. 4D) . The reduction in the mEPSC frequency suggested that Ab is causing a reduction in synapse number, whereas the unchanged mEPSC amplitude indicated that the postsynaptic AMPA receptor composition and/or activity of the remaining synapses were probably not affected. The reduction of mEPSC frequency caused by Ab was effectively rescued by MKI-EGFP (Fig. 4D) . We note that neurons expressing MKI-EGFP alone also showed reduced mEPSC frequency but not amplitude (Fig. 4D) , suggesting that the PAR-1/MARK family kinases have a normal physiological function in hippocampal neurons and that its appropriate level is important for synaptic function.
DISCUSSION
The amyloid and tau lesions are pathological hallmarks of AD that are present in virtually all AD cases. The relationship between the two, however, remains unresolved. Accumulating evidence supports the toxic oligomers formed by the Ab peptide as the disease-causing agents, and synapses and dendritic spines as their major sites of action. Here we show that Ab acts through the PAR-1/MARK family kinases to impinge on tau to affect synaptic function and dendritic spine morphogenesis. This conclusion is supported by the suppression of Ab toxicity by either the co-expression of a phospho-mutant form of tau that can no longer be phosphorylated by PAR-1/MARK, or the specific inhibition of PAR-1/ MARK with a peptide inhibitor. Our findings are consistent with the hypothesis that tau abnormality is a major downstream pathogenic event in the signaling cascade initiated by Ab (6) , and the observation that removal of endogenous tau attenuates learning and memory deficits in AD models (18) .
One major question concerns how tau abnormality, specifically its hyperphosphorylation, leads to synaptic and dendritic spine pathology. Despite tau being best known as an axonal protein, phospho-tau was shown to accumulate in dendritic spines, where it may affect the synaptic trafficking and/or anchoring of glutamate receptors, thereby influencing postsynaptic function (40) . It is not clear whether phospho-tau is being actively transported to the dendritic compartment, or that due to its compromised ability to bind microtubules, especially after being phosphorylated by PAR-1/MARK, phosphotau simply diffuses from axon to other cellular compartments. Dendritic tau was recently found to recruit fyn kinase, facilitating fyn-mediated phosphorylation of GluR2 and stabilizing the interaction between GluR2 and PSD-95 (41). This potentially promotes excitotoxicity and represents a possible mechanism by which dendritic tau mediates Ab toxicity. It remains to be determined whether dendritic tau has a normal physiological function. Since Ab-induced spine loss was preventable by taxol (34) , tau-related microtubule destabilization and trafficking defects may also mediate Ab toxicity.
Much of the molecular events linking Ab to tau pathologies remain to be elucidated. The implication of PAR-1/MARK in this process offers a new entry point to further dissect the signaling process. Several kinases have been shown to act upstream of PAR-1/MARK (42), including LKB1 (33) . It would be interesting to test the involvement of these kinases in mediating Ab toxicity through the regulation of PAR-1/ MARK. Previous studies have indicated that tau phosphorylation at the PAR-1/MARK target sites also responds to other Human Molecular Genetics, 2012, Vol. 21, No. 6 1387 stress stimuli including osmotic stress, oxidative stress, serum deprivation and glutamate-induced excitotoxicity (33, 34) , suggesting that other triggers of the disease may also impinge on the PAR-1/MARK-tau axis. Ab could also induce reversible synapse loss by modulating an NMDA-type GluR-dependent signaling pathway (43) , or use long-term depression-related signaling mechanisms to affect synaptic function and dendritic spine morphology (44) . Whether these signaling pathways are connected to the PAR-1/MARK-tau axis will be important future research directions. It also remains to be determined whether Ab oligomers act by directly activating transmembrane receptors, changing neuronal membrane properties or, simply, causing cellular stress (4,34). Our results suggest that targeting PAR-1/MARK kinases represents a potential strategy to prevent the synaptic toxicity of Ab, thereby preventing or treating the synaptic defects of AD. In vivo studies applying MKI to various AD mouse models with clear learning and memory deficits are needed to validate this therapeutic approach. One major concern is the potential side effects, given the myriad cellular functions of PAR-1/MARK kinases (42) . This concern is warranted by our observation that although MKI restored normal neurotransmission to Ab oligomer-treated neurons, it led to reduced mEPSC frequency in mock-treated neurons, suggesting that appropriate levels of PAR-1/MARK activity is important for neurotransmission. Thus, in Ab oligomer-treated neurons, which possess elevated PAR-1/MARK activity (34) , MKI tuned down kinase activity to a level compatible with normal neurotransmission. However, in normal neurons, reduction of PAR-1/MARK activity by MKI to belowthreshold levels could compromise neurotransmission. It will therefore be necessary to adjust MKI dosages to achieve therapeutic effect without causing serious side effects. The same could be said for therapeutic approaches targeting Ab or tau. For example, the production of Ab is positively regulated by neuronal activity (45) , and Ab can in turn depress excitatory synaptic transmission (46) . This negative feedback regulatory loop may normally serve to restrain neuronal hyperactivity, such that therapeutic approaches leading to too much removal of Ab might have unwanted side effects as well.
MATERIALS AND METHODS
Hippocampal neuronal culture and transfection
Rat E18 hippocampal neuron primary cultures were prepared as described (47) . Cultured neurons (10-day in vitro) in 12-well plates were transfected with 2 -3 mg of plasmid/ well, using a CalPhos Mammalian Transfection Kit (Clontech, San Jose, CA, USA). Fluorescence immunocytochemistry was performed 3 days after transfection. Preparation and concentration of lentiviral particles were performed as described 
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Human Molecular Genetics, 2012, Vol. 21, No. 6 before (47). Viral transfection of hippocampal neurons was carried out at 10 days after in vitro culture. The next day, culture medium was replaced with 50% fresh medium plus 50% conditioned medium.
Ab oligomer preparation
Commercial Ab-42 peptide was purchased from rPeptide (Bogart, GA, USA). Ab oligomer was prepared following a published protocol (37) . Briefly, Ab-42 was dissolved in hexafluoroisopropanol (HFIP) at 4 mg/ml and aliquoted into 0.6 ml tubes. Peptide films were obtained by evaporating HFIP with a Speed VAC and stored at 2808C. Prior to use, the peptide was dissolved in phosphate buffer (pH 7.4) to 80 mM and incubated at 48C for 24 h. Culture medium containing 5 mM Ab was used to treat neurons.
Recombinant DNA construction
EGFP-tagged PSD-95-WT in the FHUGW lentivirus vector was described before (35) . The S561A mutation was introduced by site-directed mutagenesis. Tau S2A mutations were introduced as described before (25), and subcloned into FHUGW with a C-terminal HA tag. EGFP-and HA-tagged human MARK4 constructs were obtained from Dr Gerard Drewes. MKI cDNA was obtained from Dr C. Erec Stebbins, and subcloned into FHUGW vector with a C-terminal EGFP tag.
Immunofluorescence analysis
Chicken anti-EGFP (1:4000) and rabbit anti-HA (1:3000) antibodies were purchased from Abcam (Cambridge, MA, USA); mouse anti-Myc (1:1500, 4A6) and mouse anti-PSD-95 (1:300) from Millipore (Billerica, MA, USA); rabbit antiGluR1 (1:200) from Calbiochem (San Diego, CA, USA) and rabbit anti-Synapsin I (1: 1000) from Sigma (St Louis, MO, USA). Immunofluorescence analysis was done essentially as described before (47) . Confocal images were obtained using a Leica TCS SP5 confocal microscope or Zeiss inverted LSM510 confocal microscope (Carl Zeiss, Inc.) with 63× NA 1.4 objectives. Processed confocal images were used to make 2D projections. Dendritic spine number and clusters of PSD-95, GluR1 or Synapsin I were manually counted as the number along a 10 mm length of dendrite and presented as mean + SEM. Each experiment was done at least three times and six to nine neurons were randomly selected for analysis each time. Between 15 and 30 dendritic processes were selected for quantification. Data were analyzed while blind to the conditions.
Electrophysiology in dissociated cultures
Whole-cell patch-clamp recordings were made from neurons at 13 -14 DIV in voltage clamp mode using a Multiclamp 700B amplifier (Molecular Devices, Union City, CA, USA), digitized at 10 kHz and filtered at 4 kHz. Data were acquired and analyzed using AxographX (Axograph, Sydney , picrotoxin (100 mM) and 1 mM tetrodotoxin in the bath solution. All recordings were performed at a holding potential of 270 mV at room temperature. mEPSCs were identified using a template with a threshold of 26 pA (2.5 × SD of the noise) and were individually proofread for accuracy. To plot summary graphs, the average frequency from the EGFP control cells from each culture preparation was normalized. Individual cells from all four conditions were then compared with this normalized average.
